Seldon CS, Colbert LE, Hall WA, Fisher SB, Yu DS, Landry JC. Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World J Gastrointest Oncol 2016; 8(4): 358-365 [PMID: 27096031 DOI: 10.4251/wjgo.v8.i4.358]
Corresponding Author of This Article
Jerome C Landry, MD, MBA, Assistant Professor, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, NE, Suite C3008, Atlanta, GA 30322, United States. jland01@emory.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2016; 8(4): 358-365 Published online Apr 15, 2016. doi: 10.4251/wjgo.v8.i4.358
Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas
Crystal S Seldon, Lauren E Colbert, William A Hall, Sarah B Fisher, David S Yu, Jerome C Landry
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States
Lauren E Colbert, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
William A Hall, Department of Radiation Oncology, the Medial College of Wisconsin, Milwaukee, WI 53226, United States
Sarah B Fisher, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, United States
Author contributions: Seldon CS wrote the paper; Colbert LE, Hall WA, Fisher SB, Yu DS and Landry JC equally contributed to this paper with data collection, design, review, editing and approval of the final version.
Supported by The National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers ULl TR000454 previously awarded to Dr. Colbert and Dr. Fisher and TLlTR000456 to Dr. Colbert; and Pancreatic Cancer Action Network (Pan-CAN)&solAmerican Association for Cancer Research (AACR) award 16982, Department of Defense (DOD)/ Peer Reviewed Cancer Research Program (PRCRP) award CA110535, and Georgia Cancer Coalition award 11072, all to Dr. Yu.
Conflict-of-interest statement: No potential conflicts of interest were disclosed.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jerome C Landry, MD, MBA, Assistant Professor, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, NE, Suite C3008, Atlanta, GA 30322, United States. jland01@emory.edu
Telephone: +1-404-6166349 Fax: +1-404-6166380
Received: July 28, 2015 Peer-review started: July 29, 2015 First decision: November 3, 2015 Revised: December 5, 2015 Accepted: January 8, 2016 Article in press: January 11, 2016 Published online: April 15, 2016 Processing time: 246 Days and 8.5 Hours
Abstract
Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. These markers can be used clinically to optimize and personalize therapy for individual patients. In this review, we focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain-like protein. The aim of this article is to review present literature provided for these biomarkers and current studies in which their effectiveness as prognostic biomarkers are analyzed in order to determine their future use as biomarkers in clinical medicine. Based on the data presented, these biomarkers warrant further investigation, and should be validated in future studies.
Core tip: Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in studies and research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. We focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain-like protein. Based on the data presented, these biomarkers warrant further investigation.
